PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative Colitis
Status:
Terminated
Trial end date:
2019-04-24
Target enrollment:
Participant gender:
Summary
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic
inflammation limited to colonic mucosa. Its pathogenesis is not still clear, even if a
multifactorial aetiology has been advocated. The aim of this study is to evaluate the
long-term efficacy of two different doses of VSL#3® added on standard therapy (5-ASA) in
maintaining remission in an adult population of patients with UC, compared with the standard
therapy (5-ASA) plus placebo. The investigators hypothesized that adding VSL#3® to mesalamine
would lead to higher remission rate at long-term evaluation.